Chris Gale has been funded by the University of Edinburgh to lead the UK arm of an international registry-based randomised controlled trial (RRCT).
It is expected that this study will also receive external funding from other grant giving bodies. The trial will be the first international cardiovascular RRCT.
With collaborators in Canada and Australia, it aims to recruit 9000 patients over 60 hospitals cluster randomised to test the hypothesis that the systematic use of the GRACE risk score will 1) increase the adherence to guideline recommended therapies for NSTEACS and 2) reduce MACCE rates.
The recently published TASTE trial (N Eng J Med 2013;369:1587) highlighted the success of this new approach to RCTs. The study will build on this format using national electronic healthcare records data from the National Institute for Cardiovascular Outcomes Research (NICOR) registries, Hospital Episode Statistics (HES) and the Office for National Statistics (ONS) at a fraction of the cost of a conventional RCT.